High‐dose chemotherapy for relapsed germ cell tumours: outcomes in low‐volume specialized centres

To report treatment patterns and survival outcomes of patients with relapsed and refractory metastatic germ cell tumours (GCTs) treated with high‐dose chemotherapy (HDCT) and autologous stem‐cell transplantation in low‐volume specialized centres within the widely dispersed populations of Australia and New Zealand between 1999 and 2019.

[1]  N. Lawrentschuk.  Centralisation of complex urological surgery and understanding the three Es: is it inevitable? , 2021, BJU international.

[2]  Chad A. LaGrange,et al.  Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  D. Jäger,et al.  Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease , 2018, Oncotarget.

[4]  D. Feldman,et al.  Conventional-Dose versus High-Dose Chemotherapy for Relapsed Germ Cell Tumors , 2018, Advances in urology.

[5]  M. Spahn,et al.  Response to first-line treatment and histology are associated with achieving complete remission after the first salvage high-dose chemotherapy in relapsing germ cell tumor patients , 2018, Bone Marrow Transplantation.

[6]  W. Lowrance,et al.  Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Barni,et al.  Salvage treatment for testicular cancer with standard- or high-dose chemotherapy: a systematic review of 59 studies , 2017, Medical Oncology.

[8]  N. Hanna,et al.  High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Berney,et al.  The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high‐dose chemotherapy as consolidation: a non‐cisplatin‐based induction approach , 2016, BJU international.

[10]  N. Hanna,et al.  Testicular cancer--discoveries and updates. , 2014, The New England journal of medicine.

[11]  S. Daneshmand,et al.  Association of higher institutional volume with improved overall survival in clinical stage III testicular cancer: Results from the National Cancer Data Base (1998-2011). , 2014 .

[12]  S. Fosså,et al.  Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  C. Bokemeyer,et al.  Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Powles,et al.  Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Bains,et al.  TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Daugaard.  Management of poor‐prognosis or relapsed germ‐cell cancer , 2009, BJU international.

[17]  C. Bokemeyer,et al.  High‐dose chemotherapy in nonseminomatous germ cell cancer , 2009, BJU international.

[18]  A. Oshima,et al.  Hospital procedure volume and prognosis with respect to testicular cancer patients: a population‐based study in Osaka, Japan , 2008, Cancer science.

[19]  S. Perkins,et al.  High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. , 2007, The New England journal of medicine.

[20]  M. Bains,et al.  Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  W. Siegert,et al.  A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  L. Collette,et al.  Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. , 1999, Journal of the National Cancer Institute.

[23]  E. Feuer,et al.  Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer. , 1999, Journal of the National Cancer Institute.

[24]  S. Kaye,et al.  Management of malignant teratoma: does referral to a specialist unit matter? , 1993, The Lancet.

[25]  L. Baldetorp,et al.  Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Y. Lotan,et al.  Impact of hospital case volume on testicular cancer outcomes and practice patterns. , 2018, Urologic oncology.

[27]  C. Stiller.  Non-specialist units, clinical trials and survival from testicular cancer. , 1995, European journal of cancer.